BACKGROUND: Vitamin D (VitD) deficiency is common following biliopancreatic diversion (BPD). We conducted a prospective open-label study to evaluate the efficacy of a single intramuscular injection with 600,000 IU of cholecalciferol in an arachis oil depot formulation (VitD3, Arachitol Solvay Pharmacia) as an adjunct to regular oral VitD supplementation (Citrical+D) for a period of 12 months following BPD surgery. METHODS: Some 29 patients who had undergone BPD during 2000-2005 were recruited and received a single injection of 600,000 IU of cholecalciferol. Venous blood VitD, parathyroid hormone (PTH), alkaline phosphatase (ALP), ionised calcium and urinary N-telopeptide (NTX) were assessed at baseline and at 1.5, 3, 6, 9 and 12 months post-injection. Bone mineral density (BMD) was determined at baseline and 12 months post-injection. RESULTS: VitD concentrations (mean +/- SD) were significantly increased from baseline values (61.5 +/- 18.8 nmol/L) at 1.5 months (92.4 +/- 21.5, p < 0.001), 3 months (100.5 +/- 24.4, p < 0.001) and 6 months (79.1 +/- 20.9, p = 0.014) post-injection, with non-significant elevations at 9 months (73.3 +/- 15.1, p = 0.248) and 12 months (73.4 +/- 17.3, p = 0.278). The proportion of patients with 'normalised' VitD levels was significantly higher at all post-injection time points (range, 93-100%) compared with baseline (71.4%; p < 0.01). Ionised calcium and ALP remained within normal levels at baseline and all follow-up time points, although ionised calcium decreased by 3.4% (p = 0.015) and ALP increased by 14.6% (p = 0.021) at 12 months compared with baseline. No significant change in PTH, NTX or BMD was observed. CONCLUSIONS: Intramuscular cholecalciferol injection, as an adjunct to oral supplementation, appears a safe and effective method to increase and maintain VitD levels after BPD.
BACKGROUND:Vitamin D (VitD) deficiency is common following biliopancreatic diversion (BPD). We conducted a prospective open-label study to evaluate the efficacy of a single intramuscular injection with 600,000 IU of cholecalciferol in an arachis oil depot formulation (VitD3, Arachitol Solvay Pharmacia) as an adjunct to regular oral VitD supplementation (Citrical+D) for a period of 12 months following BPD surgery. METHODS: Some 29 patients who had undergone BPD during 2000-2005 were recruited and received a single injection of 600,000 IU of cholecalciferol. Venous blood VitD, parathyroid hormone (PTH), alkaline phosphatase (ALP), ionised calcium and urinary N-telopeptide (NTX) were assessed at baseline and at 1.5, 3, 6, 9 and 12 months post-injection. Bone mineral density (BMD) was determined at baseline and 12 months post-injection. RESULTS:VitD concentrations (mean +/- SD) were significantly increased from baseline values (61.5 +/- 18.8 nmol/L) at 1.5 months (92.4 +/- 21.5, p < 0.001), 3 months (100.5 +/- 24.4, p < 0.001) and 6 months (79.1 +/- 20.9, p = 0.014) post-injection, with non-significant elevations at 9 months (73.3 +/- 15.1, p = 0.248) and 12 months (73.4 +/- 17.3, p = 0.278). The proportion of patients with 'normalised' VitD levels was significantly higher at all post-injection time points (range, 93-100%) compared with baseline (71.4%; p < 0.01). Ionised calcium and ALP remained within normal levels at baseline and all follow-up time points, although ionised calcium decreased by 3.4% (p = 0.015) and ALP increased by 14.6% (p = 0.021) at 12 months compared with baseline. No significant change in PTH, NTX or BMD was observed. CONCLUSIONS: Intramuscular cholecalciferol injection, as an adjunct to oral supplementation, appears a safe and effective method to increase and maintain VitD levels after BPD.
Authors: Amanda J Samanek; Emma J Croager; Peter Gies; Elizabeth Milne; Richard Prince; Anthony J McMichael; Robyn M Lucas; Terry Slevin Journal: Med J Aust Date: 2006-04-03 Impact factor: 7.738
Authors: Juan Ybarra; Joan Sánchez-Hernández; Ignasi Gich; Alberto De Leiva; Xavier Rius; Jose Rodríguez-Espinosa; Antonio Pérez Journal: Obes Surg Date: 2005-03 Impact factor: 4.129
Authors: Jason M Johnson; James W Maher; Isaac Samuel; Deborah Heitshusen; Cornelius Doherty; Robert W Downs Journal: J Gastrointest Surg Date: 2005-11 Impact factor: 3.452
Authors: O Lozano; J D García-Díaz; E Cancer; I Arribas; J L Rubio; I González-García; M Galván; J Alvarez; A Martín-Duce Journal: Obes Surg Date: 2007-05 Impact factor: 4.129
Authors: Hinali Zaveri; Amit Surve; Daniel Cottam; Austin Cottam; Walter Medlin; Christina Richards; LeGrand Belnap; Samuel Cottam; Benjamin Horsley Journal: Obes Surg Date: 2018-10 Impact factor: 4.129